glp-1 and gip receptor agonist Schematic illustration of monoagonists, dual agonists triple GLP1-GIP receptor co-agonists: a promising

Gianni M, Koken MHM, Chelbi-Alix MK, Benoit G, Lanotte M, Chen Z et al

In 2021, semaglutide was approved by FDA for weight loss and quickly achieved commercial success

The most common combination is Synapse + NeuroFocus & Flow (Semax + Selank) for patients who want both structural neural improvement (synaptogenesis via Dihexa) and real-time cognitive performance enhancement (neurotransmitter modulation via Semax/Selank)

Maintain a Balanced Diet: Include Vitamin B-rich foods like whole grains, eggs, dairy, and green leafy vegetables

Want an energy boost

Semaglutide demonstrated a 20% MACE reduction in the SELECT trial